CoChat

Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver‐selective thyroid hormone receptor agonist eprotirome

Open access
Angelin, Bo, Kristensen, Jens D., Eriksson, Mats, Carlsson, Bo, Klein, Irwin, Olsson, Anders G., Chester Ridgway, E., Ladenson, Paul W. · 2015 · Journal of Internal Medicine
Cited by 55

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: Liver‐selective thyromimetic agents could provide a new approach for treating dyslipidaemia. Methods: We performed a multicentre, randomized, placebo‐controlled, double‐blind study to evaluate the efficacy and safety of eprotirome, a liver‐selective thyroid hormone receptor agonist, in 98 patients with primary hypercholesterolaemia. After previous drug wash‐out and dietary run‐in, patients received 100 or 200 μg day−1 eprotirome or placebo for 12 weeks. The primary end‐point was change in serum LDL cholesterol; secondary end‐points included changes in other lipid parameters and safety measures. Results: Eprotirome treatment at 100 and 200 μg daily reduced serum LDL cholesterol levels by 23 ± 5% and 31 ± 4%, respectively, compared with 2 ± 6% for placebo (P < 0.0001). Similar reductions were seen in non‐HDL cholesterol and apolipoprotein (apo) B, whereas serum levels of HDL cholesterol and apo A‐I were unchanged. There were also considerable reductions in serum triglycerides and lipoprotein(a), in particular in patients with elevated levels at baseline. There was no evidence of adverse effects on heart or bone and no changes in serum thyrotropin or triiodothyronine, although the thyroxine level decreased. Low‐grade increases in liver enzymes were evident in most patients. Conclusion: In hypercholesterolaemic patients, the liver‐selective thyromimetic eprotirome decreased serum levels of atherogenic lipoproteins without signs of extra‐hepatic side effects. Selective stimulation of hepatic thyroid hormone receptors may be an attractive way to modulate lipid metabolism in hyperlipidaemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/joim.12261

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 55

Metadata

Authors
Angelin, B., Kristensen, J. D., Eriksson, M., Carlsson, B., Klein, I., Olsson, A. G., Chester Ridgway, E., & Ladenson, P. W.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2014-05-16
Volume
277
Issue
3
Pages
331-342
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2144581648
Cited by
55
References
8
FWCI
5.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver‐selective thyroid hormone receptor agonist eprotirome. https://app.cochat.ai/papers/10.1111/joim.12261
The paper
Angelin, B., Kristensen, J. D., Eriksson, M., Carlsson, B., Klein, I., Olsson, A. G., Chester Ridgway, E., & Ladenson, P. W. (2015). Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver‐selective thyroid hormone receptor agonist eprotirome. Journal of Internal Medicine. https://doi.org/10.1111/joim.12261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.